Baxter International Inc.

3 days ago · marketbeat.com

Baxter International NYSE: BAX raised its full-year 2026 outlook after reporting third-quarter sales and adjusted earnings that exceeded its expectations, citing broad-based growth across its portfolio, improving execution and strong free cash flow generation.

4 days ago · zacks.com

BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.

4 days ago · seekingalpha.com

Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript

4 days ago · benzinga.com

Baxter International Inc. (NYSE:BAX) on Thursday reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.

4 days ago · zacks.com

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

4 days ago · zacks.com

Baxter International (BAX) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.69 per share a year ago.

4 days ago · businesswire.com

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. “We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger founda.

7 days ago · zacks.com

Baxter International Inc. BAX is scheduled to release third-quarter 2026 results on Oct. 29, before the opening bell. In the last reported quarter, the company's earnings beat the Zacks Consensus Estimate by 55.6%.

20 days ago · seekingalpha.com

Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.

26 days ago · businesswire.com

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter's website at www.